Search Results - "Schreder, M."

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER‐DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM) by Ludwig, H., Kainz, S., Zojer, N., Schreder, M., Hinke, A.

Get full text

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM) by Krönke, J, Kuchenbauer, F, Kull, M, Teleanu, V, Bullinger, L, Bunjes, D, Greiner, A, Kolmus, S, Köpff, S, Schreder, M, Mügge, L-O, Straka, C, Engelhardt, M, Döhner, H, Einsele, H, Bassermann, F, Bargou, R, Knop, S, Langer, C

“…Lenalidomide is an immunomodulatory compound with high clinical activity in multiple myeloma. Lenalidomide binding to the Cereblon (CRBN) E3 ubiquitin ligase…”
Get full text

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing by Zamò, A, Pischimarov, J, Schlesner, M, Rosenstiel, P, Bomben, R, Horn, H, Grieb, T, Nedeva, T, López, C, Haake, A, Richter, J, Trümper, L, Lawerenz, C, Klapper, W, Möller, P, Hummel, M, Lenze, D, Szczepanowski, M, Flossbach, L, Schreder, M, Gattei, V, Ott, G, Siebert, R, Rosenwald, A, Leich, E

“…Depending on disease stage follicular lymphoma (FL) lack the t(14;18) in ~15–~50% of cases. Nevertheless, most of these cases express BCL2. To elucidate…”
Get full text

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders by Rawstron, Andy C, Orfao, Alberto, Beksac, Meral, Bezdickova, Ludmila, Brooimans, Rik A, Bumbea, Horia, Dalva, Klara, Fuhler, Gwenny, Gratama, Jan, Hose, Dirk, Kovarova, Lucie, Lioznov, Michael, Mateo, Gema, Morilla, Ricardo, Mylin, Anne K, Omede, Paola, Pellat-Deceunynck, Catherine, Andres, Martin Perez, Petrucci, Maria, Ruggeri, Marina, Rymkiewicz, Grzegorz, Schmitz, Alexander, Schreder, Martin, Seynaeve, Carine, Spacek, Martin, de Tute, Ruth M, Van Valckenborgh, Els, Weston-Bell, Nicky, Owen, Roger G, San Miguel, Jesus F, Sonneveld, Pieter, Johnsen, Hans E, on behalf of European Myeloma Network

“…1 The HMDS, Leeds Teaching Hospitals NHS Trust, Leeds, UK 2 General Cytometry Service, Department of Medicine and Cancer Research Center (IBMCC), University of…”
Get full text

P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS by Schneller, A., Bolomsky, A., Zojer, N., Schreder, M., Ludwig, H.

Get full text

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma by Knop, S, Langer, C, Engelhardt, M, Mügge, L-O, Reichle, A, Rösler, W, Bassermann, F, Hertenstein, B, Kunitz, A, Röllig, C, Ostermann, H, Schäfer-Eckart, K, Ringhoffer, M, Günther, A, Junghanss, C, Biersack, H, Schreder, M, Liebert, A, Held, S, Einsele, H, Bargou, R C

Get full text

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA ‐ SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION by Pfeiffer, C., Beer, P., Asnagli, H., Bolomsky, A., Grandits, A., Schneller, A., Huber, J., Zojer, N., Schreder, M., Parker, A., Ludwig, H.

Get full text

The chemokine CXCL9 (MIG) is an independent predictor of overall survival in newly diagnosed multiple myeloma by Bolomsky, A, Schreder, M, Zojer, N, Ludwig, H

Get full text

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON‐ELIGIBLE PATIENTS WITH NDMM (AGMT‐MM02 TRIAL) by Ludwig, H., Melchardt, T., Sormann, S., Zojer, N., Andel, J., Hartmann, B., Tinchon, C., Gunsilius, E., Podar, K., Egle, A., Willenbacher, W., Wöll, E., Schreder, M., Ruckser, R., Bozic, B, Krauth, M.‐T., Petzer, A., Schmitt, C, Machherndl‐Spandl, S., Agis, H., Fillitz, M., Pönisch, W., Knop, S., Paiva, B., Greil, R.

Get full text

Preclinical Analysis of Feasibility and Efficacy of CS1 Directed CAR T cell Therapy in Multiple Myeloma in the Autologous Setting by Danhof, S, Gogishvili, T, Koch, S, Schreder, M, Knop, S, Einsele, H, Hudecek, M

Get full text

Efficacy and Safety of Pre-approval Carfilzomib-Based Therapy of Multiple Myeloma in Daily Practice – Experience from a German Academic Center by Danhof, S, Schreder, M, Rasche, L, Strifler, S, Einsele, H, Knop, S

Get full text

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma by Ludwig, H, Strasser-Weippl, K, Schreder, M, Zojer, N

Get full text

The Contribution of a Third Autologous Stem Cell Transplant in the Era of Novel Agents: Favourable Overall Survival and Improvement of Exhausted Bone Marrow Function by Strifler, S, Hilgendorf, I, Kleber, M, Röllig, C, Mügge, L.O, Teleanu, V, Danhof, S, Schreder, M, Einsele, H, Knop, S

Get full text

Expression of MUM1 IRF4 mRNA as a prognostic marker in patients with multiple myeloma by Heintel, D, Zojer, N, Schreder, M, Strasser-Weippl, K, Kainz, B, Vesely, M, Gisslinger, H, Drach, J, Gaiger, A, Jäger, U, Ludwig, H

Get full text

An agent-based model approach to multi-phase life-cycle for contact inhibited, anchorage dependent cells by Hoehn, Ross. D., Schreder, Ashley. M., Rez, Mohammed Fayez Al, Kais, Sabre

“…Cellular agent-based models are a technique that can be easily adapted to describe nuances of a particular cell type. Within we have concentrated on the…”
Get full text

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma by Chari, Ajai, Vogl, Dan T, Gavriatopoulou, Maria, Nooka, Ajay K, Yee, Andrew J, Huff, Carol A, Moreau, Philippe, Dingli, David, Cole, Craig, Lonial, Sagar, Dimopoulos, Meletios, Stewart, A. Keith, Richter, Joshua, Vij, Ravi, Tuchman, Sascha, Raab, Marc S, Weisel, Katja C, Delforge, Michel, Cornell, Robert F, Kaminetzky, David, Hoffman, James E, Costa, Luciano J, Parker, Terri L, Levy, Moshe, Schreder, Martin, Meuleman, Nathalie, Frenzel, Laurent, Mohty, Mohamad, Choquet, Sylvain, Schiller, Gary, Comenzo, Raymond L, Engelhardt, Monika, Illmer, Thomas, Vlummens, Philip, Doyen, Chantal, Facon, Thierry, Karlin, Lionel, Perrot, Aurore, Podar, Klaus, Kauffman, Michael G, Shacham, Sharon, Li, Lingling, Tang, Shijie, Picklesimer, Carla, Saint-Martin, Jean-Richard, Crochiere, Marsha, Chang, Hua, Parekh, Samir, Landesman, Yosef, Shah, Jatin, Richardson, Paul G, Jagannath, Sundar

“…Selinexor, a drug that inhibits nuclear export of tumor suppressor proteins, was tested in a phase 2 trial involving patients with myeloma whose disease had…”
Get full text

Studies on the Chemistry of Thienoannelated O,N- and S,N-Containing Heterocycles. Part 19[1]: Thieno[2,3-b][1,4]thiazines with Calcium Antagonistic and Potassium Opening Activities by Erker, Thomas, Schreder, Maria E., Studenik, Christian

“…In this study novel substituted 6‐benzyl‐thieno[2,3‐b][1,4]thiazines with an urea moiety were synthesized. Structural modifications of the amino side chain…”
Get full text

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy by Danhof, Sophia, Strifler, Susanne, Hose, Dorothea, Kortüm, Martin, Bittrich, Max, Hefner, Jochen, Einsele, Hermann, Knop, Stefan, Schreder, Martin

“…Based on ELOQUENT-2, combination therapy with the monoclonal antibody elotuzumab was approved for relapsed/refractory multiple myeloma in the US and Europe…”
Get full text

Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation by Wagner-Drouet, Eva, Teschner, Daniel, Wolschke, Christine, Janson, Dietlinde, Schäfer-Eckart, Kerstin, Gärtner, Johannes, Mielke, Stephan, Schreder, Martin, Kobbe, Guido, Kondakci, Mustafa, Hilgendorf, Inken, von Lilienfeld-Toal, Marie, Klein, Stefan, Heidenreich, Daniela, Kreil, Sebastian, Verbeek, Mareike, Grass, Sandra, Ditschkowski, Markus, Gromke, Tanja, Koch, Martina, Lindemann, Monika, Hünig, Thomas, Schmidt, Traudel, Rascle, Anne, Guldan, Harald, Barabas, Sascha, Deml, Ludwig, Wagner, Ralf, Wolff, Daniel

“…Recurrence of cytomegalovirus reactivation remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation…”
Get full text

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance by Ludwig, Heinz, Pönisch, Wolfram, Egle, Alexander, Knop, Stefan, Schreder, Martin, Lechner, Daniel, Hajek, Roman, Gunsilius, Eberhard, Fridrik, Michael A., Petzer, Andreas, Weisel, Katja C., Niederwieser, Dietger, Hinke, Axel, Greil, Richard, Zojer, Niklas

“…Keywords: quality of life, multiple myeloma, ixazomib, thalidomide, dexamethasone Introduction: Health-related quality of life in patients with multiple…”
Get full text